Speaker
Dr. Paul Liknaitzky, leading psychedelic researcher at Monash, spearheads transformative clinical trials and novel therapies in Australia.
Dr. Paul Liknaitzky, leading psychedelic researcher at Monash, spearheads transformative clinical trials and novel therapies in Australia.
Dr. Gerhard Gründer, psychiatrist at CIMH Mannheim, pioneers advanced imaging and psychedelic research in severe mental disorders.
Dr. Julie Holland, NYT-bestselling psychiatrist and MAPS advisor, pioneers MDMA and cannabis-assisted therapies.
Josh Hardman, founder of Psychedelic Alpha, offers data-driven insights on psychedelics, spanning business, policy, and research.
Dr. Maria Beckman, psychologist at Karolinska, researches psilocybin therapies and therapist–patient dynamics in clinical trials.
Dr. Leor Roseman, researcher at University of Exeter, merges neuroscience, anthropology, and conflict resolution in psychedelic studies.
Dr. David Nutt, Prof. of Neuropsychopharmacology at Imperial College, pioneers breakthroughs from GABA to psychedelics.
Dr. Christoffer Timmermann, researcher at University College London, leads the DMT Research Group exploring psychedelics’ effects on brain and mind.
Licensed psychologist specialized in neuropsychology, active in psilocybin research, therapy training, and psychedelic integration.
MD and PhD student studying psilocybin for cancer-related depression, focusing on clinical effects, expectancy, and brain changes in CAPSI trial.
Dr. Hendricks studies psilocybin for addiction, pain, and demoralization, focusing on vulnerable groups and leads multiple clinical trials at UAB.
Oxford psychiatrist researching mood disorders and psychedelics; led Compass Pathways' phase IIb trial and is among the top 1% most cited researchers.